Cleveland Clinic

The director of the Center for Neurological Restoration at Cleveland Clinic spoke to how identifying care gaps in Parkinson disease patients is not a niche issue, but part of a bigger problem.

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the findings of his presentation at AAN 2021.

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed topline results from the EMPhASIS trial of IMU-838.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, outlined the different tests that make up the MSPT battery.

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.

Critically ill patients who were obtunded, stuporous, or comatose had pediatric lateralized epileptiform discharges, and acute brain insults were among many clinical characteristics to benefit from longer EEG.

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed whether lenalidomide, a repurposed cancer drug, has promise as an Alzheimer disease DMT.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The findings suggest the externally altered proprioceptive feedback in forced exercises may be increasing cortical engagement.

Alise Carlson, MD, a resident at Cleveland Clinic, discussed her presentation from ACTRIMS Forum 2021 on the misdiagnosis of adult-onset genetic leukodystrophies as multiple sclerosis.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the research opportunities for repurposed anti-inflammatory drugs for Alzheimer disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic provided an overview on how lenalidomide, an FDA-approved cancer drug, will be evaluated in Alzheimer disease.

The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.

The duo from Cleveland Clinic discussed the reasons for choosing cycling as part of their newly initiated clinical trial, as well as what has been observed for home-based exercise interventions.

The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.

Surgical treatment for epilepsy has been proven its effectiveness, and preoperative evaluation has sparked a debate: to spare or not to spare the hippocampus?

The director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic shared the next steps in building on previous research that links exercise with a reduced Alzheimer disease risk.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

The neurologist from Cleveland Clinic discussed how patients with early-onset NMOSD were more likely to have severe residual vision loss.

A duo of researchers from Cleveland Clinic outlined their new 5-year study that tests home-based intervention in high-risk individuals for Alzheimer disease.

The neurologist from Cleveland Clinic discussed how her study reinforced previous findings that individuals with early onset neuromyelitis optica spectrum disorders are more likely to experience severe vision loss.